Experiments conducted on mice and HUVECs demonstrated that SR-717 administration could partially counteract the inhibitory effects of GSDME deficiency on atherosclerosis, vascular inflammation, and ox-LDL-induced endothelial cell inflammation. Here, GSDME is linked to atherosclerosis.